Rep, M H <br/><br/>
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.  [electronic resource] 

 -  The Journal of clinical investigation  May 1997 
 - 2225-31 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0021-9738 
<br/><br/><label>Standard No.: </label>10.1172/JCI119396  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>CD4 Antigens--immunology<br/>CD4-Positive T-Lymphocytes--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Interferon-gamma--biosynthesis<br/>Interleukin-4--biosynthesis<br/>Leukocyte Common Antigens--immunology<br/>Lymphocyte Depletion<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis--immunology<br/>T-Lymphocyte Subsets--immunology<br/>Th1 Cells--immunology<br/>Th2 Cells--immunology<br/>fas Receptor--immunology